תאריך: 18/10/2018 - 19/10/2018
Chairpersons: Dror Harats and Sergio Fazio
What you don't know about PCSK9
What you don't know about PCSK9Sergio Fazio
Oregon Health & Science University, USA
Identifying the patients who may benefit most from PCSK9 inhibition
Identifying the patients who may benefit most from PCSK9 inhibitionYehuda Kamari
Sheba Medical Center, Israel
Optimizing cholesterol lowering therapy in patients who report adverse muscle events
Optimizing cholesterol lowering therapy in patients who report adverse muscle eventsRobert S. Rosenson
Icahn School of Medicine at Mount Sinai, USA
Safety and efficacy of Apixaban in very high-risk populations – Emerging data and therapeutic concepts
Safety and efficacy of Apixaban in very high-risk populations – Emerging data and therapeutic conceptsShaul Atar
Galilee Medical Center, Israel
